Cellectar presents Phase 2b iopofosine data in relapsed/refractory Waldenström macroglobulinemia
Cellectar Biosciences presented efficacy data from a Phase 2b CLOVER WaM subset analysis of iopofosine I 131 in patients relapsed or refractory to BTK inhibitor therapy at the International Workshop for Waldenström Macroglobulinemia.